• Mashup Score: 0

    Hepatocyte growth and proliferation depends on membrane phospholipid biosynthesis. Short chain fatty acids (SCFA) generated by bacterial fermentation, delivered through the gut-liver axis, significantly contribute to lipid biosynthesis. We therefore hypothesized that dysbiotic insults like antibiotics treatment not only affect gut microbiota, but also impair hepatic lipid synthesis and liver…

    Tweet Tweets with this article
    • #GastroEdPick Researchers have investigated the role of the #gutmicrobiota in hepatic membrane phospholipid biosynthesis and liver regeneration in mice @JHepatology https://t.co/i4sLsnCWxy

  • Mashup Score: 4

    The risk of developing variceal bleeding (and rebleeding) in patients with advanced chronic liver disease depends on the degree of portal hypertension, which can be assessed by measuring the hepatic venous pressure gradient (HVPG) at hepatic vein catheterization (normal ⩽5mmHg) [1]. Varices and other complications of portal hypertension do not develop until HVPG is of at least 10mmHg. These…

    Tweet Tweets with this article
    • RT @ApoThera: Esophageal varices:Stage-dependent treatment algorithm https://t.co/zG0iD9BU6A #MedTwitter #MedEd #GITwitter #USMLE #healthca…

  • Mashup Score: 44

    Traditionally, the diagnosis of renal dysfunction in cirrhosis is defined as a 50% increase in serum creatinine (SCr) with a final SCr of ⩾1.5mg/dl (133μmol/L) [1]. However, smaller rises in SCr have also been shown to have a negative prognostic impact in decompensated cirrhosis, especially in patients with infection [2]. Therefore, the International Club of Ascites, in line with other…

    Tweet Tweets with this article
    • RT @ApoThera: New diagnostic criteria and management of acute kidney injury https://t.co/WyNCWW3l75 #MedTwitter #MedEd #medstudents #medica…

  • Mashup Score: 15

    Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases (NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also regress liver disease. Weight reductions of ⩾10% can induce a near universal non-alcoholic steatohepatitis resolution and fibrosis improvement by at least one stage. However, modest weight loss (>5%) can also produce…

    Tweet Tweets with this article
    • RT @MichaelAlbertMD: Treat-to-target for NAFLD/NASH: 🔑 is ≥ 10% weight loss. https://t.co/9yp3clzwpU https://t.co/VTkAesYItT